Pages that link to "Q36573818"

The following pages link to Lenalidomide in multiple myeloma (Q36573818):

Displaying 20 items.

• Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function (Q28383385) (← links)
• Interleukin-6 in bone metastasis and cancer progression. (Q34051820) (← links)
• Bone marrow microenvironment and the identification of new targets for myeloma therapy (Q36162703) (← links)
• Emerging drugs in multiple myeloma (Q36758600) (← links)
• Treatment strategies in elderly patients with multiple myeloma: current status (Q36951934) (← links)
• Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma (Q36975064) (← links)
• Thromboembolic events with lenalidomide-based therapy for multiple myeloma (Q37038367) (← links)
• Lenalidomide and its role in the management of multiple myeloma (Q37183439) (← links)
• Vascular complications of selected cancer therapies (Q37293135) (← links)
• Treatment of relapsed and refractory myeloma (Q37738580) (← links)
• Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice (Q37991783) (← links)
• Sequential or combination therapy for multiple myeloma (Q38059253) (← links)
• Choosing treatment options for patients with relapsed/refractory multiple myeloma (Q38170453) (← links)
• Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies (Q38580545) (← links)
• Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide (Q39571840) (← links)
• High-throughput approaches to discover novel immunomodulatory agents for cancer (Q42403258) (← links)
• Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. (Q43078127) (← links)
• Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (Q43726973) (← links)
• Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. (Q43979784) (← links)
• Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients (Q83498653) (← links)